logo
ProjectForthcoming

Quantitative Multispectral Optoacoustic Tomography

Forthcoming · Germany, France, United Kingdom

Source: EU Funding & Tenders Portal

"Q-MSOT aims to deliver the first handheld optoacoustic tomography system capable of true quantification of tissue chromophores and achieving unprecedented imaging depths (>4 cm) non-invasively in human tissue. Q-MSOT directly addresses two longstanding limitations of optoacoustic imaging: lack of quantification and insufficient penetration. Quantification is enabled by the novel SCOR algorithm, w

Status
Prospective
Sector
Commercial
Location
Germany
Updated
19 Nov 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Quantitative Multispectral Optoacoustic Tomography

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Quantitative Multispectral Optoacoustic Tomography” is an infrastructure initiative in the Commercial sector, located in Germany, France, United Kingdom. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

forthcoming

Taiyo status

Prospective

Taiyo last update

2026-11-19

Contact

Not available for this record.

Description

Description

"Q-MSOT aims to deliver the first handheld optoacoustic tomography system capable of true quantification of tissue chromophores and achieving unprecedented imaging depths (>4 cm) non-invasively in human tissue. Q-MSOT directly addresses two longstanding limitations of optoacoustic imaging: lack of quantification and insufficient penetration. Quantification is enabled by the novel SCOR algorithm, which solves the spectral-coloring problem in bio-optics, while deeper penetration is achieved through an optimized ultrasound detector with per-element pre-amplification. Building on results from the EIC Pathfinder project SWOPT (#101046667), Q-MSOT advances the technology from TRL 3 to TRL 5, translating innovative algorithms and hardware into clinical applications, and maturing the business readiness from BRL 3 to BRL 5. The system will enable quantitative readouts of tissue oxygenation and aerobic metabolism in vivo, with significant impact for cancer treatment monitoring and cardiometabolic disease diagnostics. The project includes validation in phantoms, animal models, and pilot human studies, focusing on breast cancer radiotherapy side effect monitoring and muscle bioenergetics. Q-MSOT also features a robust business and IP strategy, aiming for broad clinical adoption, regulatory compliance, and market readiness. The consortium integrates expertise in optoacoustic system design and algorithm development, clinical application, detector development, software, and commercialization, positioning Q-MSOT to set a new standard in quantitative bio-optical imaging and drive European leadership in the field."

Location

Country

Germany

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Commercial

Article published date

2026-09-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project